Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Filip Knop MD, PhD

Filip K. Knop MD, PhD

Professor, Consultant Endocrinologist, and Director, Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

Filip K. Knop, MD, PhD, is a professor of endocrinology and director of Center for Clinical Metabolic Research at Gentofte Hospital, University of Copenhagen, and consultant endocrinologist at Steno Diabetes Center Copenhagen.

Prof. Knop has been involved in diabetes, obesity, and metabolic research since his fellowship at The Distinguished Gifford Laboratories for Diabetes Research, University of Texas, Southwestern Medical Center in Dallas in 1999 (supervised by Christopher B. Newgard). Knop received his MD degree in 2002 and his PhD in medical sciences in 2007 from University of Copenhagen (supervisor: Jens J. Holst).

Knop’s research centres on human metabolism, the pathophysiology of obesity and related disorders including type 2 diabetes and non-alcoholic fatty liver disease, regulation of appetite and food intake, and the therapeutic potential of factors involved in these processes. The Knop laboratory has reported several novel findings describing the integrative role of the gut and the liver in human (patho)physiology.

Prof. Knop has authored more than 440 peer-reviewed scientific publications and he has received multiple honours for his research (e.g. named “Rising star” by the European Association for the Study of Diabetes (EASD) in 2010, the DPLU/LUDC Nordic Prize for an Outstanding Young Diabetes Investigator (2011), Johan Quentin and Wife’s Prize for Outstanding Research (2014), The Capital Region of Denmark’s Global Excellence Prize (2014), The Thomsen Prize (2015), The Niels Schwartz Sørensen Prize (2017), The Danish Odd Fellowship’s Research Prize (2017), the European Journal of Endocrinology Prize 2018, and EASD’s Minkowski Prize 2019).

Disclosures

Dr. Knop has served on scientific advisory panels and/or been part of speaker’s bureaus for, served as a consultant to and/or received research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, Lupin, MedImmune, MSD/Merck, Mundipharma, Norgine, Novo Nordisk, Pharmacosmos, Sanofi, ShouTi, Zealand Pharma and Zucara; and is a minority shareholder in Antag Therapeutics and co-owner of the weight loss clinic Medicinsk Vægttabsbehandling ApS.